Reported Monday, Dec 1 - 8:22am EST (TheFly subscription required to read more.)

BioNexus (Nasdaq: BGLC) reported progress toward commercializing the VitaGuard™ molecular residual disease (MRD) liquid‑biopsy platform in Southeast Asia after a working visit to Tongshu Gene facilities and Chinese hospitals where VitaGuard is in paid commercial use. The visit, led by Fidelion’s Chief Commercial Officer, focused on technical planning, workflows, documentation, reagents, and commercial routes.Under a November 2025 assignment, Fidelion holds VitaGuard IP rights outside China and has licensed BioNexus exclusive commercialization rights in ten Southeast Asian markets, covering use, development, manufacture, marketing and sale. BioNexus also owns about 15% of Fidelion, giving it direct regional and indirect global exposure.BioNexus has previously indicated an expected cost per VitaGuard test of under US$300, subject to local factors, and sees potential for repeat MRD monitoring across a regional population of over 680 million. The company is preparing documentation transfer, local verification/validation, and regulatory steps in Malaysia and Singapore, targeting initial deployments in select regional medical hubs during 2026, subject to approvals.

Breakthrough VitaGuard platform slashes cancer monitoring costs by 90%. Strategic alliance targets Southeast Asia's 2.4M annual cancer cases. See expansion details.

VitaGuard A encapsulates retinol to improve stability, limit irritation, and enhance skin bioavailability. Clinically proven to reduce forehead wrinkles by 37 per cent and boost skin elasticity by 16 per cent. Offers superior anti-aging benefits…

VitaGuard A encapsulates retinol to improve stability, limit irritation, and enhance skin bioavailability. Clinically proven to reduce forehead wrinkles by 37 per cent and boost skin elasticity by 16 per cent. Offers superior anti-aging benefits…